MAP2K7 and melanoma: There have been no clinical trials directly comparing the effectiveness of immunotherapy versus BRAF inhibitor and MEK inhibitor in BRAF-mutant advanced melanoma; therefore, the best sequence of therapy in this patient group remains unknown.